Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to clear painful hand and foot pustules

NCT ID NCT03633396

Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested a monthly injection called imsidolimab (ANB019) in 59 adults with palmoplantar pustulosis, a chronic skin condition causing painful, pus-filled blisters on the palms and soles. The study compared the drug to a placebo to see if it could reduce the severity of the pustules and scaling. Researchers also monitored safety and side effects over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
imsidolimab (ANB019)
What this could lead to
If it works, this could point toward a new treatment option for palmoplantar pustulosis, a chronic skin condition causing painful pustules on hands and feet.
What could go wrong
This is a small, early-phase trial with only 59 participants. Results may not apply to everyone, and the drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

59 people

The number who actually took part.

Started

May 2019

Finished

Apr 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinically confirmed diagnosis of PPP * Disease duration of at least 6 months prior to screening * Present with active pustules on palms or/and soles at screening Exclusion Criteria: * Any other ongoing inflammatory disease that interfere with the investigator's ability to evaluate the subject's response to therapy * History of recurrent or active/serious infection * Ongoing use of psoriasis prohibited medication Other protocol-defined inclusion/exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Palmoplantar pustulosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

palmoplantar pustulosis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Palmoplantar pustulosis

Contacts and locations

Locations

  • Investigational Site

    Birmingham, Alabama, 35233, United States

  • Investigational Site

    Phoenix, Arizona, 85032, United States

  • Investigational Site

    Encino, California, 91436, United States

  • Investigational Site

    Santa Monica, California, 90405, United States

  • Investigational Site

    Fort Lauderdale, Florida, 33316, United States

  • Investigational Site

    Miami, Florida, 33155, United States

  • Investigational Site

    Pembroke Pines, Florida, 33028, United States

  • Investigational Site

    Tampa, Florida, 33607, United States

  • Investigational Site

    Indianapolis, Indiana, 46250, United States

  • Investigational Site

    Plainfield, Indiana, 46168, United States

  • Investigational Site

    Overland Park, Kansas, 66215, United States

  • Investigational Site

    Ann Arbor, Michigan, 48109, United States

  • Investigational Site

    St Louis, Missouri, 63110, United States

  • Investigational Site

    St Louis, Missouri, 63117, United States

  • Investigational Site

    Wilmington, North Carolina, 28405, United States

  • Investigational Site

    Columbus, Ohio, 43230, United States

  • Investigational Site

    Norman, Oklahoma, 73071, United States

  • Investigational Site

    Portland, Oregon, 97239, United States

  • Investigational Site

    Dallas, Texas, 75230, United States

  • Investigational Site

    Surrey, British Columbia, Canada

  • Investigational Site

    Greater Sudbury, Ontario, Canada

  • Investigational Site

    Markham, Ontario, Canada

  • Investigational Site

    Drummondville, Quebec, Canada

  • Investigational Site

    Montreal, Quebec, Canada

  • Investigational Site

    Bad Bentheim, 48455, Germany

  • Investigational Site

    Berlin, 10117, Germany

  • Investigational Site

    Berlin, 10789, Germany

  • Investigational Site

    Bonn, 53127, Germany

  • Investigational Site

    Hamburg, 20253, Germany

  • Investigational Site

    Hamburg, 22391, Germany

  • Investigational Site

    Schwerin, 19055, Germany

  • Investigational Site

    Gdansk, 80-546, Poland

  • Investigational Site

    Katowice, 40-611, Poland

  • Investigational Site

    Lodz, 90-265, Poland

  • Investigational Site

    Olsztyn, 10-229, Poland

  • Investigational Site

    Ostrowiec Świętokrzyski, 27-400, Poland

  • Investigational Site

    Rzeszów, 35-055, Poland

  • Investigational Site

    Szczecin, 70-332, Poland

  • Investigational Site

    Wroclaw, 50-566, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.